Here’s What Medicover AB (publ)’s (STO:MCOV B) P/E Is Telling Us

Today, we’ll introduce the concept of the P/E ratio for those who are learning about investing. We’ll show how you can use Medicover AB (publ)’s (STO:MCOV B) P/E ratio to inform your assessment of the investment opportunity. What is Medicover’s P/E ratio? Well, based on the last twelve months it is 48.53. In other words, at today’s prices, investors are paying SEK48.53 for every SEK1 in prior year profit.

View our latest analysis for Medicover

How Do I Calculate Medicover’s Price To Earnings Ratio?

The formula for P/E is:

Price to Earnings Ratio = Share Price (in reporting currency) ÷ Earnings per Share (EPS)

Or for Medicover:

P/E of 48.53 = €7.9 (Note: this is the share price in the reporting currency, namely, EUR ) ÷ €0.16 (Based on the trailing twelve months to June 2019.)

Is A High Price-to-Earnings Ratio Good?

A higher P/E ratio implies that investors pay a higher price for the earning power of the business. All else being equal, it’s better to pay a low price — but as Warren Buffett said, ‘It’s far better to buy a wonderful company at a fair price than a fair company at a wonderful price.’

Does Medicover Have A Relatively High Or Low P/E For Its Industry?

One good way to get a quick read on what market participants expect of a company is to look at its P/E ratio. The image below shows that Medicover has a significantly higher P/E than the average (16) P/E for companies in the healthcare industry.

OM:MCOV B Price Estimation Relative to Market, August 5th 2019
OM:MCOV B Price Estimation Relative to Market, August 5th 2019

Medicover’s P/E tells us that market participants think the company will perform better than its industry peers, going forward.

How Growth Rates Impact P/E Ratios

If earnings fall then in the future the ‘E’ will be lower. Therefore, even if you pay a low multiple of earnings now, that multiple will become higher in the future. So while a stock may look cheap based on past earnings, it could be expensive based on future earnings.

Medicover shrunk earnings per share by 17% over the last year. And it has shrunk its earnings per share by 6.5% per year over the last five years. This might lead to muted expectations.

A Limitation: P/E Ratios Ignore Debt and Cash In The Bank

It’s important to note that the P/E ratio considers the market capitalization, not the enterprise value. That means it doesn’t take debt or cash into account. Theoretically, a business can improve its earnings (and produce a lower P/E in the future) by investing in growth. That means taking on debt (or spending its cash).

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

So What Does Medicover’s Balance Sheet Tell Us?

Medicover has net debt worth 17% of its market capitalization. This could bring some additional risk, and reduce the number of investment options for management; worth remembering if you compare its P/E to businesses without debt.

The Bottom Line On Medicover’s P/E Ratio

Medicover has a P/E of 48.5. That’s higher than the average in its market, which is 16.3. With a bit of debt, but a lack of recent growth, it’s safe to say the market is expecting improved profit performance from the company, in the next few years.

When the market is wrong about a stock, it gives savvy investors an opportunity. People often underestimate remarkable growth — so investors can make money when fast growth is not fully appreciated. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

You might be able to find a better buy than Medicover. If you want a selection of possible winners, check out this free list of interesting companies that trade on a P/E below 20 (but have proven they can grow earnings).

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.